Nutrition and health

Objectives:
Lutein and zeaxanthin are thought to have beneficial effects on protecting the lens against cataract formation, but findings from epidemiologic studies have been inconsistent. Therefore, this review article has been conducted.

Does dietary lutein and zeaxanthin intake reduce age-related cataract risk?

Study design:
This review article included 6 prospective cohort studies, involving 4416 cases and 41999 participants.

Results and conclusions:
The investigators found for comparing the highest with the lowest categories of dietary lutein and zeaxanthin intake, a significant reduced risk for nuclear cataract of 25% [RR = 0.75, 95% CI = 0.65-0.85], but the reduced risk was not significant for cortical cataract [RR = 0.85, 95% CI = 0.53-1.17] and for posterior subcapsular cataract [RR = 0.77, 95% CI = 0.40-1.13]. Significant means, there is an association with a 95% confidence.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was significantly associated with a 3% [RR = 0.97, 95% CI = 0.94-0.99] reduction in the risk of nuclear cataract.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was non-significantly associated with a 1% [RR = 0.99, 95% CI = 0.95-1.02] reduction in the risk of cortical cataract. Non-significantly means, there is no association with a 95% confidence.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was non-significantly associated with a 3% [RR = 0.97, 95% CI = 0.93-1.01] reduction in the risk of posterior subcapsular cataract. Non-significantly because RR of 1 was found in 95% CI of 0.93 to 1.01. RR of 1 means no risk.

The investigators concluded dietary lutein and zeaxanthin intake (at least 300 μg/d) is associated with a reduced risk of age-related cataract, especially nuclear cataract in a dose-response manner, indicating a beneficial effect of lutein and zeaxanthin in age-related cataract prevention.

Original title:
A dose–response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract by Ma L, Hao ZX, [...], Pan JP.

Link:
http://link.springer.com/article/10.1007/s00417-013-2492-3

Additional information of El Mondo:
Find more studies/information on elderly right here.

Objectives:
Is there an association between serum non-ceruloplasmin copper and Alzheimer's disease risk?

Study design:
This review article included studies carried out from 1996 until March 2013.

Ten studies were analyzed in the meta-analysis for Non-Cp copper and % Non-Cp copper reaching a pooled total of 599 Alzheimer's disease subjects and 867 controls.
For Adj-Cp copper, 14 studies were analyzed with a pooled total of 879 Alzheimer's disease subjects and 1712 controls.
27 studies were considered for systemic total copper meta-analysis, with a pooled total of 1393 Alzheimer's disease subjects and 2159 controls.

Results and conclusions:
The investigators found all copper indices analyzed were significantly higher in Alzheimer's disease subjects compared to healthy controls.

The investigators concluded serum non-ceruloplasmin copper is higher in Alzheimer's disease.

Original title:
Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease by Squitti R, Simonelli I, […], Bush AI.

Link:
http://www.ncbi.nlm.nih.gov/pubmed/24072069

Additional information of El Mondo:
Find more studies/information on elderly and copper.

Objectives:
Does DHA, alone or combined with EPA, contribute to improved memory function in older adults with mild memory complaints?

Study design:
This review article included 15 intervention trials and 13 observational studies. Most intervention trials were conducted with subjects ≥ 45 years of age (n = 11). The majority of studies were conducted in subjects without cognitive complaints (n = 9) and ranged from 28-730 days in duration, averaging 4-6 months.

Results and conclusions:
The investigators found episodic memory of subjects with mild memory complaints significantly improved in response to DHA supplementation, alone or in combination with EPA [p 0.004].

The investigators found regardless of cognitive status at baseline, >1 g/day DHA/EPA significantly improved episodic memory of subjects with mild memory complaints [p 0.04].

The investigators found there was a trend for episodic memory improvement in response to supplementation in subjects 45 years or older [p 0.058].

The investigators found DHA intake above the mean DHA level studied (580 mg/day) significantly improved episodic memory in all subjects [p 0.009] and in subjects with mild memory complaints [p 0.019]. Significant means that there is an association with a 95% confidence.

The investigators found observational studies supported a beneficial association between intake/blood levels of DHA/EPA and memory function in older adults.

The investigators concluded DHA (>580 mg/day), alone or combined with EPA (>1 g/day DHA/EPA), contributes to improved memory function in older adults (45 years or older) with mild memory complaints.

Original title:
Docosahexaenoic Acid and Adult Memory: A Systematic Review and Meta-Analysis by Yurko-Mauro K, Alexander DD and Van Elswyk ME.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364972/

Additional information of El Mondo:
Find more studies/information on elderly and EPA&DHA.

This meal provides at least 580 mg DHA.
1 g/day DHA/EPA corresponds to meals providing 4 days of DHA&EPA.

Episodic memory is the type of long-term, declarative memory in which we store memories of personal experiences that are tied to particular times and places.
Some examples of episodic memory:

• Your skiing vacation last winter;
• The first time you traveled by airplane;
• Your first high school day.